News & Events

Learn about what's new with CMC Biologics

AGC Biologics Appoints New Site Head/General Manager of Bothell, WA Operations

News

Jin Wang, Ph.D. named Site Head/General Manager

 

BOTHELL, Wash. – April 12, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Dr. Jin Wang as Site Head/General Manager of its Bothell, Washington operations. Ms. Wang will provide leadership and site management to ensure AGC Biologics’ continued execution of world class contract development and manufacturing services. Dr. Wang will report to Patricio Massera, Chief Operations Officer.

AGC Biologics Increases Footprint in Bothell, WA

News

Addition of new facilities supports strong company-wide growth initiative

BOTHELL, Wash. –  March 29, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the addition of a new building complex that will house the company’s global headquarters in Bothell, Washington.

AGC Biologics Appoints Two New Sr. Vice Presidents of Business Development

News

Axel Schleyer, Ph.D. named Senior Vice President of Business Development, North America
Christoph Winterhalter, Ph.D. named Senior Vice President of Business Development, Europe

BOTHELL, Wash. –  March 13, 2018 -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Axel Schleyer as Senior Vice President of Business Development, North America, and Christoph Winterhalter as Senior Vice President of Business Development, Europe. Mr. Schleyer and Mr. Winterhalter will report to Robert Broeze, Chief Business Officer.

AGC Biologics Expands Capacity at Berkeley, California Facility

News

BERKELEY, Calif., March 6, 2018 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their Berkeley, California facility is adding to its growing capacity with the addition of a 2000L single-use bioreactor (SUB).

AGC Biologics Holds Technical Seminar in South Korea

News

BOTHELL, Wash., Feb. 4, 2018 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company held its second bi-annual technical seminar in Seoul, South Korea, exclusively focused on early-phase development and manufacturing.

AGC Biologics to Hold Technical Seminar in Taiwan

News

BOTHELL, Wash., and BERKLEY, Calif., and COPENHAGEN, Denmark, and HEIDELBERG, Germany, and CHIBA, Japan, and YOKOHAMA, Japan, Jan. 21, 2018 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will hold a technical seminar in Taipei City, Taiwan, exclusively focused on early-phase development and manufacturing.

AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics

News

BOTHELL, Wash., BERKLEY, Calif., COPENHAGEN, DK, HEIDELBERG, DE, CHIBA & YOKOHAMA, JAPAN ─ January 8, 2018 ─ AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, announced today that effective January 8, 2018, the company will be integrated and newly branded as 
AGC Biologics.

CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics

News

BOTHELL, Wash., BERKELEY, Calif., and SOUTH SAN FRANCISCO, Calif., USA -- December 12, 2017 -- CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Harpoon Therapeutics, an immuno-oncology company using its proprietary TriTAC™ technology platform to discover and develop novel biologics for the treatment of cancer, announced today they have entered into an agreement for the development and manufacturing of HPN424, HPN536, and HPN217, representing three TriTAC™ molecules for the treatment of various human cancers.

CMC Biologics and Aptevo Therapeutics Enter into Commercial Manufacturing Agreement for IXINITY®

News

Bothell, WA and Seattle, WA – August 22, 2017 – CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and Aptevo Therapeutics (Nasdaq: APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that they have entered into an agreement for the continued commercial manufacture of Aptevo’s factor IX therapeutic, IXINITY® Coagulation Factor IX (Recombinant). 

CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience

News

Development of Trellis’ monoclonal antibody (mAb) using CMC Biologics’ proprietary CHEF1® Expression Platform and Multi-column Continuous Chromatography (MCC) Technology

 

 

Follow Us
Join us on LinkedIn Follow us on Twitter